Single Covid-19 jab produces antibodies in 96 per cent of people
The figures will give yet more confidence that the vaccines are the way out of the pandemic.
Over 96 per cent of people who get a single dose of the Covid-19 vaccines made by Astrazeneca or Pfizer develop antibodies, a new study has shown.
The figure rises to 99 per cent when a second shot has been administered, the trial, which was carried out by scientists at University College London, found.
The results of the survey of 8,517 people in England and Wales were reported by the Guardian.
In total, 96.42 per cent of participants developed antibodies within 28 to 34 days of receiving their first vaccination.